The Beginners’ Portfolio: What If We’d Bought AstraZenenca plc?

Did we do well to choose GlaxoSmithKline plc (LON: GSK) ahead of AstraZeneca plc (LON: AZN)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

This article is the latest in a series that aims to help novice investors with the stock market. To enjoy past articles in the series, please visit our full archive.

The Beginners’ Portfolio is a virtual portfolio, which is run as if based on real money with all costs, spreads and dividends accounted for.

One thing you should definitely do, especially when you’re still learning the ropes, is look back at your previous decisions and ask “What if…?”

With a few of our decisions, we’ve been torn between the top two companies in a sector, and we’re getting far enough in now to look back and see how we’d have done had we made the opposite choice.

The best Big Pharma?

astrazenecaIt’s nearly 16 months since I plumped for GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) over AstraZenenca (LSE: AZN) (NYSE: AZN.US), so how would the portfolio be looking now if I’d made the opposite decision?

On 12 June 2012, we picked up GlaxoSmithKline shares for a purchase price of 1,440.5p, and on the same day we could have had AstraZeneca for an estimated 2,666p (going on the mid-price, and assuming similar spread to today). For our £500, we’d have been able to buy 18 shares for a total price of £429.33.

Today, with the price having slipped back over the past couple of months after good progress, GlaxoSmithKline shares would sell for 1,551.5p apiece, with AstraZeneca shares fetching 3,128p. After charges, if we’d bought AstraZenenca shares and we sold today, we’d be up 12.3%, while in reality we’re only up 3% from GlaxoSmithKline.

Dividends too

Then there are dividends, and GlaxoSmithKline has added £31.62 to the pot so far. Over the same period, we’d have had £42.97 from AstraZeneca, so we have the loser on both counts. In fact, the comparison looks like this:

Company Buy Sell Change Divi Total %
GlaxoSmithKline £502.22 £517.51 £15.29 £31.62 £46.91 9.3%
AstraZeneca £492.33 £533.04 £60.71 £42.97 £103.68 21%

(Note this compares total values of the investment, not share prices)

Today’s valuation

So what does current valuation look like? Here are the figures, based on current forecasts:

GlaxoSmithKline EPS % P/E Divi Yield Cover
2013 116p +2% 13.4 77p 5.0% 1.51x
2014 127p +10% 12.2 82p 5.3% 1.55x
AstraZeneca EPS % P/E Divi Yield Cover
2013 321p -20% 9.8 181p 5.7% 1.78x
2014 301p -6% 10.4 182p 5.7% 1.65x

(Source: Digital Look)

AstraZenenca would clearly have been a better investment over the past 16 months, and it’s arguable that it looks better valued on these forecasts, too. And over the short term, I think I would go along with that.

But I think what we’re really looking at here is one company that has been doing everything right, moving with the technology, positioning itself correctly for the future, and bringing in rising earnings — that’s GlaxoSmithKline, and its valuation reflects that success.

AstraZenenca, on the other hand, has seen where it is going wrong and is taking steps to refocus on its key strengths — and I have to say I’ve been impressed by new chief executive Pascal Soriot so far. But we’re not there yet and it will take time, and we really need to see a return to earnings growth to regain confidence.

AstraZenenca shares are probably oversold right now and they do look better value in the short term. But GlaxoSmithKline has the better pipeline and is ahead technologically, and for the long term I think it’s better to pay more for higher quality and lower risk.

I’m still happy with our choice.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Alan does not own any shares mentioned in this article. The Motley Fool has recommended shares in Vodafone and GlaxoSmithKline.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

3 UK stocks I reckon could benefit from the upcoming general election

As the general election hurtles towards us, this Fool wonders which UK stocks could benefit, and focuses on three picks…

Read more »

BUY AND HOLD spelled in letters on top of a pile of books. Alongside is a piggy bank in glasses. Buy and hold is a popular long term stock and shares strategy.
Investing Articles

At 11%, this dividend share pays the biggest yield in the FTSE 100

When a dividend share offers a big yield, we need to be cautious of the risks. But I reckon this…

Read more »

British Isles on nautical map
Investing Articles

I reckon Hiscox shares could be one of the best bargains on the FTSE

I've been investing in FTSE companies for years, but after a major decline I've not seen a company with as…

Read more »

Grey Number 4 Stencil on Yellow Concrete Wall
Investing Articles

4 reasons I’d still buy National Grid shares in a heartbeat despite the recent wobble!

As National Grid shares plunged on the news of a right issue, I’m not flinching, and reckon it's a top…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

After gaining 45% in 12 months, is the Amazon share price now overvalued?

Our author thinks the Amazon share price might be too high. While the long-term future of the business looks bright,…

Read more »

Investing Articles

2 hot dividend stocks I’d buy and hold for 10 years

Our writer reckons these two dividend stocks could help her bag juicy dividends for years to come and explains why.

Read more »

British Pennies on a Pound Note
Investing Articles

2 dividend-paying penny shares I’d happily own

These two penny shares have caught our writer's eye for a combination of income prospects now and business growth potential…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

This FTSE 250 share looks like a bargain to me!

This FTSE 250 share has seen its price tumble due to chaotic local economic conditions in a key market. But…

Read more »